Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned an average rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $61.33.

Several research analysts have commented on ARCT shares. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. Citigroup increased their price objective on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $26.32 on Friday. The company has a fifty day moving average of $35.42 and a 200 day moving average of $29.75. Arcturus Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $43.81. The company has a market capitalization of $708.53 million, a P/E ratio of -25.31 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. The business had revenue of $33.99 million during the quarter, compared to the consensus estimate of $64.14 million. Analysts forecast that Arcturus Therapeutics will post -1.42 EPS for the current year.

Insider Activity

In other news, COO Pad Chivukula sold 8,565 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $35.01, for a total transaction of $299,860.65. Following the sale, the chief operating officer now directly owns 490,883 shares in the company, valued at approximately $17,185,813.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 13.80% of the company’s stock.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. MetLife Investment Management LLC raised its position in Arcturus Therapeutics by 66.3% in the 1st quarter. MetLife Investment Management LLC now owns 12,327 shares of the biotechnology company’s stock worth $332,000 after purchasing an additional 4,915 shares during the period. Dimensional Fund Advisors LP raised its position in Arcturus Therapeutics by 190.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 217,572 shares of the biotechnology company’s stock worth $5,866,000 after purchasing an additional 142,633 shares during the period. Vanguard Group Inc. raised its position in Arcturus Therapeutics by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,153,513 shares of the biotechnology company’s stock worth $31,099,000 after purchasing an additional 6,291 shares during the period. Federated Hermes Inc. raised its position in Arcturus Therapeutics by 1.8% in the 1st quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company’s stock worth $101,421,000 after purchasing an additional 66,971 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Arcturus Therapeutics by 2.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 154,551 shares of the biotechnology company’s stock worth $4,167,000 after acquiring an additional 3,704 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.